Skip to content

Search

Congratulations Dr Lea-Ann Kirkham - Robert Austrian Award Winner

Congratulations to Dr Lea-Ann Kirkham - one of just 10 recipients from around the world to receive a prestigious Robert Austrian Award at the International Symposium on Pneumococci and Pneumococcal Diseases.

Whooping cough studies

How protective is the whooping cough vaccine? Vaccination and allergy Even though Australia has high vaccination rates against whooping cough, we

Scholarships

Find out more about the scholarship opportunities at the Wesfarmers Centre, including Training Scholarships and Higher Degree by Research Scholarships.

2018 Round 2 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful recipients for the 2018 Round 2 Seed Funding Grants. The Wesfarmers Centre Scientific

2018 Round 1 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful applications for the 2018 Round 1 Wesfarmers Centre Seed Funding. The Wesfarmers Centre

2016 Round 1 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the 4 successful applications for the 2016 Round 1 Wesfarmers Centre Seed Funding.

Resources

Wesfarmers Centre of Vaccines & Infectious Diseases resources

Rheumatic Heart Disease Endgame Strategy: what does it mean to community?

Across Australia, more than 5,000 Aboriginal and Torres Strait Islander people are currently living with rheumatic heart disease (RHD) or its precursor, acute rheumatic fever (ARF).

New pneumococcal vaccine closes in on approval

Pneumococcal – a bacterial infection that can cause pneumonia and meningitis – is responsible for 1000s of hospital admissions in Australia each year, many of them children.

Understanding parental decisions to decline or delay infant RSV immunisation, nirsevimab, in Western Australia in 2024

In 2024, the government of Western Australia introduced 'nirsevimab', a monoclonal antibody offering protection from respiratory syncytial virus (RSV), for eligible infants. This study explores why parents of infants who were eligible to receive nirsevimab opted to decline or delay the immunisation.